




RealRate

PHARMACEUTICAL 2022

Landos Biopharma Inc.
Rank 260 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai

**RealRate**

PHARMACEUTICAL 2022

Landos Biopharma Inc.
Rank 260 of 475



The relative strengths and weaknesses of Landos Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Landos Biopharma Inc. compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 51% points. The greatest weakness of Landos Biopharma Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 127% points.

The company's Economic Capital Ratio, given in the ranking table, is -134%, being 142% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	92,146
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,611
Liabilities, Non-Current	0
Other Assets	26
Other Compr. Net Income	159
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Property and Equipment	707
Research and Development	41,564
Revenues	18,000
Selling, General and Administrative Expense	15,252

Output Variable	Value in 1000 USD
Assets	92,879
Liabilities	16,611
Expenses	56,816
Stockholders Equity	76,268
Net Income	-38,816
Comprehensive Net Income	-38,736
Economic Capital Ratio	-134%

**RealRate**

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai